person · Reporting owner

Vuori Kristiina MD

Disclosed activity across 6 companies

Tapewire entity: 41223
SEC CIK: 0001612627

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Bionano Genomics, Inc.BNGO · Entity 7831	Director	May 14, 2026	May 14, 2026
Inhibrx Biosciences, Inc.INBX · Entity 4576	Director	June 03, 2026	September 18, 2026
Sio Gene Therapies Inc.SIOX · Entity 130622	Director	April 15, 2021	April 19, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Bionano Genomics, Inc.

Report date May 14, 2026 · Filed May 14, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.19 · Expires 2036-05-13	Direct	9,149	Reported balance After 2026-05-14 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-14 · Grant · Acquired 9,149 · Balance 9,149 F1: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the option holder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan).

Filing footnotes · ownership attribution and instrument terms

F1: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the option holder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan).

Inhibrx Biosciences, Inc.

Report date June 03, 2026 · Filed September 18, 2026 · Amendment

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $95.22 · Expires 2036-06-03	Direct	10,000	Reported balance After 2026-06-03 transaction · row 1 Amendment: may correct only part of an earlier disclosure. 1 source row Row 1 · 2026-06-03 · Grant · Acquired 10,000 · Balance 10,000 F1: This stock option will be fully exercisable on June 3, 2027, subject to the reporting person's continued service through such date.

Filing footnotes · ownership attribution and instrument terms

F1: This stock option will be fully exercisable on June 3, 2027, subject to the reporting person's continued service through such date.

Sio Gene Therapies Inc.

Report date April 15, 2021 · Filed April 19, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.47 · Expires 2031-04-14	Direct	42,000	Reported balance After 2021-04-15 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-04-15 · Grant · Acquired 42,000 · Balance 42,000 F1: 100% of this option will vest on April 15, 2022, subject to the Reporting Person providing continuous service to the Issuer on such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested shares of common stock. All shares of common stock underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan.

Filing footnotes · ownership attribution and instrument terms

F1: 100% of this option will vest on April 15, 2022, subject to the Reporting Person providing continuous service to the Issuer on such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested shares of common stock. All shares of common stock underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Forian Inc.

Report date May 15, 2026 · Filed May 15, 2026

Section 16 reporting ended · disclosed 2026-05-15. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2026-05-15 transaction · row 1 1 source row Row 1 · 2026-05-15 · Other · Disposed 28,757 · Balance 0 F1: Pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated April 2, 2026, by and between Forian Inc., a Maryland corporation (the "Issuer"), 2025 Acquisition Company, LLC, a Delaware limited liability company ("Parent"), and Bravo Merger Sub, Inc., a Maryland corporation and wholly owned subsidiary of Parent ("Merger Sub"), on May 15, 2026, Parent and Merger Sub completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders received $2.17 per Share (the "Offer Price"), payable in cash, without interest and subject to any applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.06 · Expires 2035-03-26	Direct	Reported balance After 2026-05-15 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-05-15 · Disposition to issuer · Acquired 15,000 · Balance 0 F2: On May 15, 2026, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each vested stock option that had an exercise price per Share that was less than the Offer Price and that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash (without interest and subject to deduction for any required withholding taxes), equal to the product of: (i) the total number of Shares subject to such option, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Share under such option. F3: At the Effective Time, each stock option that was either (i) unvested or (ii) that had a per share exercise price per Share that was equal to or more than the Offer Price that was then outstanding and unexercised as of immediately prior to the Effective Time was cancelled without any consideration payable therefor.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.20 · Expires 2034-03-27	Direct	Reported balance After 2026-05-15 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-05-15 · Disposition to issuer · Acquired 15,000 · Balance 0 F3: At the Effective Time, each stock option that was either (i) unvested or (ii) that had a per share exercise price per Share that was equal to or more than the Offer Price that was then outstanding and unexercised as of immediately prior to the Effective Time was cancelled without any consideration payable therefor.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.14 · Expires 2033-03-23	Direct	Reported balance After 2026-05-15 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-05-15 · Disposition to issuer · Acquired 15,000 · Balance 0 F3: At the Effective Time, each stock option that was either (i) unvested or (ii) that had a per share exercise price per Share that was equal to or more than the Offer Price that was then outstanding and unexercised as of immediately prior to the Effective Time was cancelled without any consideration payable therefor.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.81 · Expires 2032-03-17	Direct	Reported balance After 2026-05-15 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-05-15 · Disposition to issuer · Acquired 15,000 · Balance 0 F3: At the Effective Time, each stock option that was either (i) unvested or (ii) that had a per share exercise price per Share that was equal to or more than the Offer Price that was then outstanding and unexercised as of immediately prior to the Effective Time was cancelled without any consideration payable therefor.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.18 · Expires 2031-03-05	Direct	Reported balance After 2026-05-15 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-05-15 · Disposition to issuer · Acquired 15,000 · Balance 0 F3: At the Effective Time, each stock option that was either (i) unvested or (ii) that had a per share exercise price per Share that was equal to or more than the Offer Price that was then outstanding and unexercised as of immediately prior to the Effective Time was cancelled without any consideration payable therefor.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated April 2, 2026, by and between Forian Inc., a Maryland corporation (the "Issuer"), 2025 Acquisition Company, LLC, a Delaware limited liability company ("Parent"), and Bravo Merger Sub, Inc., a Maryland corporation and wholly owned subsidiary of Parent ("Merger Sub"), on May 15, 2026, Parent and Merger Sub completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders received $2.17 per Share (the "Offer Price"), payable in cash, without interest and subject to any applicable withholding taxes.

F2: On May 15, 2026, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each vested stock option that had an exercise price per Share that was less than the Offer Price and that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash (without interest and subject to deduction for any required withholding taxes), equal to the product of: (i) the total number of Shares subject to such option, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Share under such option.

F3: At the Effective Time, each stock option that was either (i) unvested or (ii) that had a per share exercise price per Share that was equal to or more than the Offer Price that was then outstanding and unexercised as of immediately prior to the Effective Time was cancelled without any consideration payable therefor.

Inhibrx, Inc.

Report date May 30, 2024 · Filed May 30, 2024

Section 16 reporting ended · disclosed 2024-05-30. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.03 · Expires 2033-05-25	Direct	Reported balance After 2024-05-30 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-05-30 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F3: This stock option was cancelled in the Merger and converted into the right to receive (A) an amount in cash, without interest and less any applicable withholding taxes, equal to the product of (x) the total number of shares of the Issuer's common stock subject to such stock option immediately prior to the effective time, multiplied by (y) the excess of (I) an amount in cash equal to $30.00, without interest thereon over (II) the exercise price payable per share of the Issuer common stock under such option and (B) one (1) contractual contingent value right for each share of the Issuer common stock subject to such stock option. F2: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on May 25, 2024, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.57 · Expires 2032-05-25	Direct	Reported balance After 2024-05-30 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-05-30 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F3: This stock option was cancelled in the Merger and converted into the right to receive (A) an amount in cash, without interest and less any applicable withholding taxes, equal to the product of (x) the total number of shares of the Issuer's common stock subject to such stock option immediately prior to the effective time, multiplied by (y) the excess of (I) an amount in cash equal to $30.00, without interest thereon over (II) the exercise price payable per share of the Issuer common stock under such option and (B) one (1) contractual contingent value right for each share of the Issuer common stock subject to such stock option. F4: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on May 25, 2023, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.45 · Expires 2031-12-07	Direct	Reported balance After 2024-05-30 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-05-30 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F6: This stock option was canceled in the Merger without any consideration being payable in respect thereof, and has no further force or effect. F5: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on December 7, 2022, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger").

F2: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on May 25, 2024, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.

F3: This stock option was cancelled in the Merger and converted into the right to receive (A) an amount in cash, without interest and less any applicable withholding taxes, equal to the product of (x) the total number of shares of the Issuer's common stock subject to such stock option immediately prior to the effective time, multiplied by (y) the excess of (I) an amount in cash equal to $30.00, without interest thereon over (II) the exercise price payable per share of the Issuer common stock under such option and (B) one (1) contractual contingent value right for each share of the Issuer common stock subject to such stock option.

F4: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on May 25, 2023, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.

F5: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on December 7, 2022, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.

F6: This stock option was canceled in the Merger without any consideration being payable in respect thereof, and has no further force or effect.

WebMD Health Corp.

Report date September 15, 2017 · Filed September 15, 2017

Section 16 reporting ended · disclosed 2017-09-15. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2017-09-15 transaction · row 1 1 source row Row 1 · 2017-09-15 · Other · Disposed 1,790 · Balance 0 F1: Sold in a tender offer made by Diagnosis Merger Sub, Inc., a Delaware Corporation ("Purchaser") and a wholly-owned subsidiary of MH Sub I, LLC, a Delaware limited liability company ("Parent"), to purchase all of the issued and outstanding shares of common stock of WebMD Health Corp., a Delaware corporation ("WebMD"), for $66.50 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of July 24, 2017, by and among WebMD, Purchaser, and Parent (the "Merger Agreement").
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.89 · Expires 2024-07-07	Direct	Reported balance After 2017-09-15 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-09-15 · Disposition to issuer · Disposed 13,200 · Balance 0 F2: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.55 · Expires 2025-01-01	Direct	Reported balance After 2017-09-15 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-09-15 · Disposition to issuer · Disposed 13,200 · Balance 0 F2: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.30 · Expires 2026-01-01	Direct	Reported balance After 2017-09-15 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2017-09-15 · Disposition to issuer · Disposed 13,200 · Balance 0 F2: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.57 · Expires 2027-01-01	Direct	Reported balance After 2017-09-15 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2017-09-15 · Disposition to issuer · Disposed 13,200 · Balance 0 F2: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD.

Filing footnotes · ownership attribution and instrument terms

F1: Sold in a tender offer made by Diagnosis Merger Sub, Inc., a Delaware Corporation ("Purchaser") and a wholly-owned subsidiary of MH Sub I, LLC, a Delaware limited liability company ("Parent"), to purchase all of the issued and outstanding shares of common stock of WebMD Health Corp., a Delaware corporation ("WebMD"), for $66.50 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of July 24, 2017, by and among WebMD, Purchaser, and Parent (the "Merger Agreement").

F2: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 03, 2026 Filed Sep 18, 2026 20:25 UTC Amendment	Inhibrx Biosciences, Inc. INBX · Entity 4576	GrantStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $95.22	$0.00	Disclosure SEC source: 0001612627-26-000007 · wk-form4a_1789763137.xml · derivative · entry 1 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2036-06-03 F1 · derivative.exercise_date: This stock option will be fully exercisable on June 3, 2027, subject to the reporting person's continued service through such date. Read SEC document
June 03, 2026 Filed Jun 4, 2026 21:29 UTC	Inhibrx Biosciences, Inc. INBX · Entity 4576	GrantStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $95.22	$0.00	Disclosure SEC source: 0001612627-26-000004 · wk-form4_1780608551.xml · derivative · entry 1 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2036-06-03 F1 · derivative.exercise_date: This stock option will be fully exercisable on June 3, 2027, subject to the reporting person's continued service through such date. Read SEC document
May 15, 2026 Filed May 15, 2026 21:24 UTC	Forian Inc. FORA · Entity 47119	Disposition to issuerStock Option (right to buy) · Derivative	15,000	Not disclosed Strike: $12.18	Not disclosed	Disclosure SEC source: 0001140361-26-021726 · form4.xml · derivative · entry 6 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2031-03-05 F3 · price: At the Effective Time, each stock option that was either (i) unvested or (ii) that had a per share exercise price per Share that was equal to or more than the Offer Price that was then outstanding and unexercised as of immediately prior to the Effective Time was cancelled without any consideration payable therefor. F3 · derivative.exercise_date: At the Effective Time, each stock option that was either (i) unvested or (ii) that had a per share exercise price per Share that was equal to or more than the Offer Price that was then outstanding and unexercised as of immediately prior to the Effective Time was cancelled without any consideration payable therefor. Read SEC document
May 15, 2026 Filed May 15, 2026 21:24 UTC	Forian Inc. FORA · Entity 47119	Disposition to issuerStock Option (right to buy) · Derivative	15,000	Not disclosed Strike: $6.81	Not disclosed	Disclosure SEC source: 0001140361-26-021726 · form4.xml · derivative · entry 5 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2032-03-17 F3 · price: At the Effective Time, each stock option that was either (i) unvested or (ii) that had a per share exercise price per Share that was equal to or more than the Offer Price that was then outstanding and unexercised as of immediately prior to the Effective Time was cancelled without any consideration payable therefor. F3 · derivative.exercise_date: At the Effective Time, each stock option that was either (i) unvested or (ii) that had a per share exercise price per Share that was equal to or more than the Offer Price that was then outstanding and unexercised as of immediately prior to the Effective Time was cancelled without any consideration payable therefor. Read SEC document
May 15, 2026 Filed May 15, 2026 21:24 UTC	Forian Inc. FORA · Entity 47119	Disposition to issuerStock Option (right to buy) · Derivative	15,000	Not disclosed Strike: $3.14	Not disclosed	Disclosure SEC source: 0001140361-26-021726 · form4.xml · derivative · entry 4 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2033-03-23 F3 · price: At the Effective Time, each stock option that was either (i) unvested or (ii) that had a per share exercise price per Share that was equal to or more than the Offer Price that was then outstanding and unexercised as of immediately prior to the Effective Time was cancelled without any consideration payable therefor. F3 · derivative.exercise_date: At the Effective Time, each stock option that was either (i) unvested or (ii) that had a per share exercise price per Share that was equal to or more than the Offer Price that was then outstanding and unexercised as of immediately prior to the Effective Time was cancelled without any consideration payable therefor. Read SEC document
May 15, 2026 Filed May 15, 2026 21:24 UTC	Forian Inc. FORA · Entity 47119	Disposition to issuerStock Option (right to buy) · Derivative	15,000	Not disclosed Strike: $3.20	Not disclosed	Disclosure SEC source: 0001140361-26-021726 · form4.xml · derivative · entry 3 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2034-03-27 F3 · price: At the Effective Time, each stock option that was either (i) unvested or (ii) that had a per share exercise price per Share that was equal to or more than the Offer Price that was then outstanding and unexercised as of immediately prior to the Effective Time was cancelled without any consideration payable therefor. F3 · derivative.exercise_date: At the Effective Time, each stock option that was either (i) unvested or (ii) that had a per share exercise price per Share that was equal to or more than the Offer Price that was then outstanding and unexercised as of immediately prior to the Effective Time was cancelled without any consideration payable therefor. Read SEC document
May 15, 2026 Filed May 15, 2026 21:24 UTC	Forian Inc. FORA · Entity 47119	Disposition to issuerStock Option (right to buy) · Derivative	15,000	Not disclosed Strike: $2.06	Not disclosed	Disclosure SEC source: 0001140361-26-021726 · form4.xml · derivative · entry 2 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2035-03-26 F2 · price: On May 15, 2026, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each vested stock option that had an exercise price per Share that was less than the Offer Price and that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash (without interest and subject to deduction for any required withholding taxes), equal to the product of: (i) the total number of Shares subject to such option, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Share under such option. F3 · price: At the Effective Time, each stock option that was either (i) unvested or (ii) that had a per share exercise price per Share that was equal to or more than the Offer Price that was then outstanding and unexercised as of immediately prior to the Effective Time was cancelled without any consideration payable therefor. F2 · derivative.exercise_date: On May 15, 2026, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each vested stock option that had an exercise price per Share that was less than the Offer Price and that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash (without interest and subject to deduction for any required withholding taxes), equal to the product of: (i) the total number of Shares subject to such option, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Share under such option. F3 · derivative.exercise_date: At the Effective Time, each stock option that was either (i) unvested or (ii) that had a per share exercise price per Share that was equal to or more than the Offer Price that was then outstanding and unexercised as of immediately prior to the Effective Time was cancelled without any consideration payable therefor. Read SEC document
May 15, 2026 Filed May 15, 2026 21:24 UTC	Forian Inc. FORA · Entity 47119	OtherCommon Stock	28,757	Not disclosed	Not disclosed	Disclosure SEC source: 0001140361-26-021726 · form4.xml · nonDerivative · entry 1 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated April 2, 2026, by and between Forian Inc., a Maryland corporation (the "Issuer"), 2025 Acquisition Company, LLC, a Delaware limited liability company ("Parent"), and Bravo Merger Sub, Inc., a Maryland corporation and wholly owned subsidiary of Parent ("Merger Sub"), on May 15, 2026, Parent and Merger Sub completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders received $2.17 per Share (the "Offer Price"), payable in cash, without interest and subject to any applicable withholding taxes. Read SEC document
May 14, 2026 Filed May 14, 2026 22:15 UTC	Bionano Genomics, Inc. BNGO · Entity 7831	GrantStock Option (Right to Buy) · Derivative	9,149	$0.00 Strike: $1.19	$0.00	Disclosure SEC source: 0001612627-26-000002 · ownership.xml · derivative · entry 1 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,149 Underlying: Common Stock · 9,149 shares Expires 2036-05-13 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the option holder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan). Read SEC document
June 11, 2025 Filed Jun 12, 2025 20:50 UTC	Bionano Genomics, Inc. BNGO · Entity 7831	GrantStock Option (Right to Buy) · Derivative	2,775	$0.00 Strike: $3.67	$0.00	Disclosure SEC source: 0001411690-25-000069 · wk-form4_1749761452.xml · derivative · entry 1 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,775 Underlying: Common Stock · 2,775 shares Expires 2035-06-10 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the option holder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan). Read SEC document
May 28, 2025 Filed May 29, 2025 20:32 UTC	Inhibrx Biosciences, Inc. INBX · Entity 4576	GrantStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $12.91	$0.00	Disclosure SEC source: 0002007919-25-000070 · wk-form4_1748550731.xml · derivative · entry 1 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2035-05-28 F1 · derivative.exercise_date: This stock option will be fully exercisable on May 28, 2026, subject to the reporting person's continued service through such date. Read SEC document
March 26, 2025 Filed Mar 28, 2025 22:55 UTC	Forian Inc. FORA · Entity 47119	GrantStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $2.06	$0.00	Disclosure SEC source: 0001140361-25-011045 · form4.xml · derivative · entry 1 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2035-03-26 F1 · derivative.exercise_date: The stock option vests in four equal annual installments beginning on March 26, 2026, subject to the Reporting Person's continued service as a non-employee director of the Issuer on each applicable vesting date Read SEC document
October 03, 2024 Filed Oct 7, 2024 20:34 UTC	Inhibrx Biosciences, Inc. INBX · Entity 4576	PurchaseCommon Stock	6,667	$15.00	$100,005.00	Disclosure SEC source: 0002007919-24-000051 · wk-form4_1728333250.xml · nonDerivative · entry 1 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,443 Read SEC document
September 11, 2024 Filed Sep 12, 2024 21:14 UTC	Inhibrx Biosciences, Inc. INBX · Entity 4576	PurchaseCommon Stock	6,457	$15.07	$97,306.99	Disclosure SEC source: 0002007919-24-000047 · wk-form4_1726175657.xml · nonDerivative · entry 2 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,776 F1 · price: The shares were purchased in multiple transactions at prices ranging from $15.00 to $15.08, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document
September 10, 2024 Filed Sep 12, 2024 21:14 UTC	Inhibrx Biosciences, Inc. INBX · Entity 4576	PurchaseCommon Stock	179	$15.00	$2,685.00	Disclosure SEC source: 0002007919-24-000047 · wk-form4_1726175657.xml · nonDerivative · entry 1 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,319 Read SEC document
August 29, 2024 Filed Sep 3, 2024 20:27 UTC	Inhibrx Biosciences, Inc. INBX · Entity 4576	PurchaseCommon Stock	7,140	$14.00	$99,960.00	Disclosure SEC source: 0001739614-24-000035 · wk-form4_1725395257.xml · nonDerivative · entry 1 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,140 Read SEC document
June 18, 2024 Filed Jun 20, 2024 20:23 UTC	Bionano Genomics, Inc. BNGO · Entity 7831	GrantStock Option (Right to Buy) · Derivative	30,000	$0.00 Strike: $0.78	$0.00	Disclosure SEC source: 0001411690-24-000035 · wk-form4_1718914977.xml · derivative · entry 1 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-06-18 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the option holder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan). Read SEC document
May 30, 2024 Filed May 30, 2024 22:23 UTC	Inhibrx, Inc. INBX · Entity 90351	Disposition to issuerStock Option (right to buy) · Derivative	30,000	Not disclosed Strike: $40.45	Not disclosed	Disclosure SEC source: 0000950142-24-001502 · es240484814_4-vuori.xml · derivative · entry 3 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2031-12-07 F1 · kind: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F6 · price: This stock option was canceled in the Merger without any consideration being payable in respect thereof, and has no further force or effect. F5 · derivative.exercise_date: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on December 7, 2022, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter. Read SEC document
May 30, 2024 Filed May 30, 2024 22:23 UTC	Inhibrx, Inc. INBX · Entity 90351	Disposition to issuerStock Option (right to buy) · Derivative	15,000	Not disclosed Strike: $12.57	Not disclosed	Disclosure SEC source: 0000950142-24-001502 · es240484814_4-vuori.xml · derivative · entry 2 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2032-05-25 F1 · kind: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F3 · price: This stock option was cancelled in the Merger and converted into the right to receive (A) an amount in cash, without interest and less any applicable withholding taxes, equal to the product of (x) the total number of shares of the Issuer's common stock subject to such stock option immediately prior to the effective time, multiplied by (y) the excess of (I) an amount in cash equal to $30.00, without interest thereon over (II) the exercise price payable per share of the Issuer common stock under such option and (B) one (1) contractual contingent value right for each share of the Issuer common stock subject to such stock option. F4 · derivative.exercise_date: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on May 25, 2023, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter. Read SEC document
May 30, 2024 Filed May 30, 2024 22:23 UTC	Inhibrx, Inc. INBX · Entity 90351	Disposition to issuerStock Option (right to buy) · Derivative	15,000	Not disclosed Strike: $23.03	Not disclosed	Disclosure SEC source: 0000950142-24-001502 · es240484814_4-vuori.xml · derivative · entry 1 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2033-05-25 F1 · kind: Under the Agreement and Plan of Merger, dated January 22, 2024 (the "Merger Agreement"), by and among Inhibrx, Inc. (the "Issuer"), Aventis Inc., a Pennsylvania corporation ("Parent") and wholly owned subsidiary of Sanofi, and Art Acquisition Sub, Inc., a Delaware corporation ("Merger Sub") and wholly owned subsidiary of Parent, following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on May 30, 2024, Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F3 · price: This stock option was cancelled in the Merger and converted into the right to receive (A) an amount in cash, without interest and less any applicable withholding taxes, equal to the product of (x) the total number of shares of the Issuer's common stock subject to such stock option immediately prior to the effective time, multiplied by (y) the excess of (I) an amount in cash equal to $30.00, without interest thereon over (II) the exercise price payable per share of the Issuer common stock under such option and (B) one (1) contractual contingent value right for each share of the Issuer common stock subject to such stock option. F2 · derivative.exercise_date: Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on May 25, 2024, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter. Read SEC document
May 30, 2024 Filed May 30, 2024 22:11 UTC	Inhibrx Biosciences, Inc. INXB · Entity 4576	GrantStock Option (right to buy) · Derivative	30,000	$0.00 Strike: $15.86	$0.00	Disclosure SEC source: 0000950142-24-001495 · es240484865_4-vuori.xml · derivative · entry 1 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-05-30 F1 · date: This stock option was granted following the consummation of the merger of Inhibrx, Inc. with a wholly owned indirect subsidiary of Sanofi. F2 · derivative.exercise_date: This stock option will be fully exercisable on May 30, 2025, subject to the reporting person's continued service through such date. Read SEC document
March 27, 2024 Filed Mar 28, 2024 23:44 UTC	Forian Inc. FORA · Entity 47119	GrantStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $3.20	$0.00	Disclosure SEC source: 0001140361-24-016324 · form4.xml · derivative · entry 1 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2034-03-27 F1 · derivative.exercise_date: The stock option vests in four equal annual installments beginning on March 27, 2025, subject to the Reporting Person's continued service as a non-employee director of the Issuer on each applicable vesting date. Read SEC document
June 14, 2023 Filed Jun 16, 2023 20:15 UTC	Bionano Genomics, Inc. BNGO · Entity 7831	GrantStock Option (Right to Buy) · Derivative	250,000	$0.00 Strike: $0.75	$0.00	Disclosure SEC source: 0001411690-23-000053 · wf-form4_168694648962541.xml · derivative · entry 1 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2033-06-14 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan). Read SEC document
May 25, 2023 Filed May 30, 2023 20:10 UTC	Inhibrx, Inc. INBX · Entity 90351	GrantStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $23.03	$0.00	Disclosure SEC source: 0001739614-23-000054 · wk-form4_1685477428.xml · derivative · entry 1 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2033-05-25 F1 · derivative.exercise_date: Twenty-five percent (25%) of the total shares subject to the stock option become exercisable on May 25, 2024, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter. Read SEC document
March 23, 2023 Filed Mar 24, 2023 22:50 UTC	Forian Inc. FORA · Entity 47119	GrantStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $3.14	$0.00	Disclosure SEC source: 0001140361-23-013814 · form4.xml · derivative · entry 1 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2033-03-23 F1 · derivative.exercise_date: The stock option vests in four equal annual installments beginning on March 23, 2024, subject to the Reporting Person's continued service as a non-employee director of the Issuer on each applicable vesting date. Read SEC document
June 09, 2022 Filed Jun 13, 2022 20:27 UTC	Bionano Genomics, Inc. BNGO · Entity 7831	GrantStock Option (right to buy) · Derivative	164,422	$0.00 Strike: $1.62	$0.00	Disclosure SEC source: 0001209191-22-036316 · doc4.xml · derivative · entry 1 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,422 Underlying: Common Stock · 164,422 shares Expires 2032-06-09 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan). Read SEC document
May 25, 2022 Filed May 26, 2022 20:34 UTC	Inhibrx, Inc. INBX · Entity 90351	GrantStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $12.57	$0.00	Disclosure SEC source: 0001739614-22-000063 · wf-form4_165359722506010.xml · derivative · entry 1 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 15,000 shares Expires 2032-05-25 F1 · derivative.exercise_date: Twenty-five percent (25%) of the total shares subject to the stock option become exercisable on May 25, 2023, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter. Read SEC document
March 17, 2022 Filed Apr 18, 2022 23:56 UTC	Forian Inc. FORA · Entity 47119	GrantStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $6.81	$0.00	Disclosure SEC source: 0001140361-22-014926 · form4.xml · derivative · entry 1 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-03-17 F1 · derivative.exercise_date: The stock option vests in four equal annual installments beginning on March 17, 2023, subject to the Reporting Person's continued service as a non-employee director of the Issuer on each applicable vesting date. Read SEC document
December 07, 2021 Filed Dec 8, 2021 00:43 UTC	Inhibrx, Inc. INBX · Entity 90351	GrantStock Option (right to buy) · Derivative	30,000	$0.00 Strike: $40.45	$0.00	Disclosure SEC source: 0001739614-21-000117 · wf-form4_163892416605245.xml · derivative · entry 1 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-12-07 F1 · derivative.exercise_date: Twenty-five percent (25%) of the total shares subject to the stock option become exercisable on December 7, 2022, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter. Read SEC document
August 17, 2021 Filed Aug 19, 2021 21:47 UTC	Bionano Genomics, Inc. BNGO · Entity 7831	GrantStock Option (right to buy) · Derivative	40,751	$0.00 Strike: $5.34	$0.00	Disclosure SEC source: 0001209191-21-052600 · doc4.xml · derivative · entry 1 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,751 Underlying: Common Stock · 40,751 shares Expires 2031-08-17 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following June 10, 2021, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan). Read SEC document
June 10, 2021 Filed Jun 14, 2021 23:10 UTC	Bionano Genomics, Inc. BNGO · Entity 7831	GrantStock Option (right to buy) · Derivative	7,528	$0.00 Strike: $7.64	$0.00	Disclosure SEC source: 0001209191-21-040389 · doc4.xml · derivative · entry 1 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,528 Underlying: Common Stock · 7,528 shares Expires 2031-06-10 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan). Read SEC document
April 15, 2021 Filed Apr 19, 2021 20:59 UTC	Sio Gene Therapies Inc. SIOX · Entity 130622	GrantStock Option (Right to Buy) · Derivative	42,000	$0.00 Strike: $2.47	$0.00	Disclosure SEC source: 0001636050-21-000051 · wf-form4_161886593930821.xml · derivative · entry 1 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2031-04-14 F1 · derivative.exercise_date: 100% of this option will vest on April 15, 2022, subject to the Reporting Person providing continuous service to the Issuer on such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested shares of common stock. All shares of common stock underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan. Read SEC document
March 05, 2021 Filed Mar 9, 2021 22:19 UTC	Forian Inc. FORA · Entity 47119	GrantStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $12.18	$0.00	Disclosure SEC source: 0001140361-21-007805 · form4.xml · derivative · entry 2 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-03-05 F2 · derivative.exercise_date: The stock option vests in four equal annual installments beginning on March 2, 2022, subject to the Reporting Person's continued service as a non-employee director of the Issuer on each applicable vesting date. Read SEC document
March 05, 2021 Filed Mar 9, 2021 22:19 UTC	Forian Inc. FORA · Entity 47119	GrantRestricted Stock Units	5,000	$0.00	$0.00	Disclosure SEC source: 0001140361-21-007805 · form4.xml · nonDerivative · entry 1 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · shares: Represents 5,000 restricted stock units which vest in four equal annual installments beginning on March 2, 2022, subject to the Reporting Person's continued service as a non-employee director of the Issuer on each applicable vesting date. Read SEC document
October 05, 2020 Filed Oct 8, 2020 01:28 UTC	Sio Gene Therapies Inc. AXGT · Entity 130622	GrantStock Option (Right to Buy) · Derivative	35,000	$0.00 Strike: $5.63	$0.00	Disclosure SEC source: 0001209191-20-054255 · doc4.xml · derivative · entry 1 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2030-10-04 F1 · derivative.exercise_date: The common shares underlying this option vest over a period of three years, with one-third of the common shares vesting on each of the first, second and third anniversaries of October 5, 2020, the date of the Reporting Person's appointment to the Issuer's Board of Directors. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying such option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan. Read SEC document
June 30, 2020 Filed Jul 3, 2020 00:37 UTC	Bionano Genomics, Inc. BNGO · Entity 7831	GrantStock Option (right to buy) · Derivative	44,470	$0.00 Strike: $0.51	$0.00	Disclosure SEC source: 0001209191-20-040769 · doc4.xml · derivative · entry 1 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,470 Underlying: Common Stock · 44,470 shares Expires 2029-06-30 F1 · derivative.exercise_date: The shares vest in equal monthly installments over a one year period such that the option is fully vested on June 30, 2021, subject to full vesting acceleration upon a change in control (as defined in Bionano Genomic's equity incentive plan). Read SEC document
June 30, 2020 Filed Jul 18, 2022 23:26 UTC Amendment	Bionano Genomics, Inc. BNGO · Entity 7831	GrantStock Option (Right to Buy) · Derivative	44,470	$0.00 Strike: $0.51	$0.00	Disclosure SEC source: 0001209191-22-042482 · doc4a.xml · derivative · entry 1 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,470 Underlying: Common Stock · 44,470 shares Expires 2030-06-30 F1 · derivative.exercise_date: The shares vest in equal monthly installments over a one year period such that the option is fully vested on June 30, 2021, subject to full vesting acceleration upon a change in control (as defined in Bionano Genomic's equity incentive plan). F2 · derivative.expiration_date: The acquisition of the reported option was reported in a Form 4 filed on July 2, 2020, which mistakenly reported the expiration date as 06/30/2029. Read SEC document
June 06, 2019 Filed Jun 10, 2019 21:31 UTC	Bionano Genomics, Inc. BNGO · Entity 7831	GrantStock Option (right to buy) · Derivative	30,274	$0.00 Strike: $2.78	$0.00	Disclosure SEC source: 0001209191-19-035894 · doc4.xml · derivative · entry 1 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,274 Underlying: Common Stock · 30,274 shares Expires 2029-06-06 F1 · derivative.exercise_date: The shares vest in equal monthly installments over a three year period such that the option is fully vested on June 6, 2022, subject to full vesting acceleration upon a change in control (as defined in Bionano Genomic's equity incentive plan). Read SEC document
September 15, 2017 Filed Sep 15, 2017 12:12 UTC	WebMD Health Corp. WBMD · Entity 12671	Disposition to issuerStock Option (right to buy) · Derivative	13,200	Not disclosed Strike: $49.57	Not disclosed	Disclosure SEC source: 0000947871-17-000724 · ss59052_4.xml · derivative · entry 5 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,200 shares Expires 2027-01-01 F2 · security: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD. F2 · price: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD. F2 · derivative.exercise_date: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD. Read SEC document
September 15, 2017 Filed Sep 15, 2017 12:12 UTC	WebMD Health Corp. WBMD · Entity 12671	Disposition to issuerStock Option (right to buy) · Derivative	13,200	Not disclosed Strike: $48.30	Not disclosed	Disclosure SEC source: 0000947871-17-000724 · ss59052_4.xml · derivative · entry 4 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,200 shares Expires 2026-01-01 F2 · security: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD. F2 · price: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD. F2 · derivative.exercise_date: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD. Read SEC document
September 15, 2017 Filed Sep 15, 2017 12:12 UTC	WebMD Health Corp. WBMD · Entity 12671	Disposition to issuerStock Option (right to buy) · Derivative	13,200	Not disclosed Strike: $39.55	Not disclosed	Disclosure SEC source: 0000947871-17-000724 · ss59052_4.xml · derivative · entry 3 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,200 shares Expires 2025-01-01 F2 · security: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD. F2 · price: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD. F2 · derivative.exercise_date: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD. Read SEC document
September 15, 2017 Filed Sep 15, 2017 12:12 UTC	WebMD Health Corp. WBMD · Entity 12671	Disposition to issuerStock Option (right to buy) · Derivative	13,200	Not disclosed Strike: $50.89	Not disclosed	Disclosure SEC source: 0000947871-17-000724 · ss59052_4.xml · derivative · entry 2 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,200 shares Expires 2024-07-07 F2 · security: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD. F2 · price: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD. F2 · derivative.exercise_date: On September 15, 2017, the merger transaction (the "Merger") contemplated by the Merger Agreement was completed and WebMD was acquired by the Purchaser and ceased to be a public company. Pursuant to the Merger Agreement, each option that was vested and exercisable immediately prior to completion of the Merger, or that vested upon completion of the Merger in accordance with its terms, was automatically cancelled in exchange for the right of the holder to receive an amount in cash equal to the excess of $66.50 over the exercise price of each such option. In connection with the completion of the Merger, each unvested option held by the Reporting Person fully accelerated. The Reporting Person no longer owns any securities issued by WebMD. Read SEC document
September 15, 2017 Filed Sep 15, 2017 12:12 UTC	WebMD Health Corp. WBMD · Entity 12671	OtherCommon Stock	1,790	$66.50	$119,035.00	Disclosure SEC source: 0000947871-17-000724 · ss59052_4.xml · nonDerivative · entry 1 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Sold in a tender offer made by Diagnosis Merger Sub, Inc., a Delaware Corporation ("Purchaser") and a wholly-owned subsidiary of MH Sub I, LLC, a Delaware limited liability company ("Parent"), to purchase all of the issued and outstanding shares of common stock of WebMD Health Corp., a Delaware corporation ("WebMD"), for $66.50 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of July 24, 2017, by and among WebMD, Purchaser, and Parent (the "Merger Agreement"). Read SEC document
January 01, 2017 Filed Jan 3, 2017 16:49 UTC	WebMD Health Corp. WBMD · Entity 12671	GrantStock Option (right to buy) · Derivative	13,200	$0.00 Strike: $49.57	$0.00	Disclosure SEC source: 0000947871-17-000010 · ss25389_4.xml · derivative · entry 1 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,200 Underlying: Common Stock · 13,200 shares Expires 2027-01-01 F1 · derivative.exercise_date: 25% of the shares underlying the option are scheduled to vest on each of the first, second, third and fourth anniversary of the date of the grant (fully vested on the 4th anniversary of the grant date). Read SEC document
December 12, 2016 Filed Dec 13, 2016 13:17 UTC	WebMD Health Corp. WBMD · Entity 12671	SaleCommon Stock	400	$53.02	$21,208.00	Disclosure SEC source: 0000947871-16-001767 · ss23257_4.xml · nonDerivative · entry 2 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,790 Read SEC document
December 12, 2016 Filed Dec 13, 2016 13:17 UTC	WebMD Health Corp. WBMD · Entity 12671	SaleCommon Stock	1,161	$53.01	$61,544.61	Disclosure SEC source: 0000947871-16-001767 · ss23257_4.xml · nonDerivative · entry 1 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,190 Read SEC document
November 15, 2016 Filed Nov 17, 2016 18:17 UTC	WebMD Health Corp. WBMD · Entity 12671	GrantCommon Stock	928	$53.83	$49,954.24	Disclosure SEC source: 0000947871-16-001698 · ss19903_4.xml · nonDerivative · entry 1 Vuori Kristiina MD · CIK 0001612627 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,351 F1 · shares: Payment of annual retainer for services as a non-employee member of the Board of Directors and its committees. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.